These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32212243)

  • 1. The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events.
    Wang A; Xu Y; Fei Y; Wang M
    Asia Pac J Clin Oncol; 2020 Aug; 16(4):201-210. PubMed ID: 32212243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
    Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
    Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
    Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
    Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
    Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
    Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors).
    Bourke JM; O'Sullivan M; Khattak MA
    Med J Aust; 2016 Nov; 205(9):418-424. PubMed ID: 27809739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].
    Wang H; Song P; Si X; Guo X; Li Y; Zhou J; Duan L; Zhang L; Wang M; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):605-614. PubMed ID: 31650941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of immune-related adverse events resulting from immune checkpoint blockade.
    Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
    Leipe J; Mariette X
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
    Martins F; Sykiotis GP; Maillard M; Fraga M; Ribi C; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
    Lancet Oncol; 2019 Jan; 20(1):e54-e64. PubMed ID: 30614479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
    Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
    Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab-induced toxicities and the gastroenterologist.
    Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
    J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events.
    Luo J; Beattie JA; Fuentes P; Rizvi H; Egger JV; Kern JA; Leung DYM; Lacouture ME; Kris MG; Gambarin M; Santomasso BD; Faleck DM; Hellmann MD
    J Thorac Oncol; 2021 Oct; 16(10):1759-1764. PubMed ID: 34265432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
    Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
    Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supportive care for patients undergoing immunotherapy.
    Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
    Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy.
    Kubo T; Hirohashi Y; Tsukahara T; Kanaseki T; Murata K; Morita R; Torigoe T
    Immunol Med; 2022 Jun; 45(2):108-118. PubMed ID: 34542015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
    Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
    J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Sandigursky S; Mor A
    Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing Immune-Related Adverse Events in Cancer Immunotherapy.
    Farmer JR
    Clin Lab Med; 2019 Dec; 39(4):669-683. PubMed ID: 31668277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.